Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients

Journal of Immunology

Volumn 189, Issue 7, 2012, Pages 3759-3766

  Kwek, Serena S ^a   Dao, Vinh ^a   Roy, Ritu ^b   Hou, Yafei ^a   Alajajian, David ^a   Simko, Jeffrey P ^a   Small, Eric J ^a   Fong, Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G ANTIBODY; IPILIMUMAB; P21 ACTIVATED KINASE 6; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN MICROARRAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY DIVERSITY; ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; CTLA-4 ANTIGEN; EPITOPES, T-LYMPHOCYTE; FEASIBILITY STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84866551703     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201529     Document Type: Article

References (29)

1. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548. (Pubitemid 40563179)
2. Brücher, J., I. Domke, C. H. Schröder, and H. Kirchner. 1984. Experimental infection of inbred mice with herpes simplex virus. VI. Effect of interferon on in vitro virus replication in macrophages. Arch. Virol. 82: 83-93. (Pubitemid 15205719)
3. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736. (Pubitemid 26102823)
4. Link, K. A., S. Balasubramaniam, A. Sharma, C. E. Comstock, S. Godoy-Tundidor, N. Powers, K. H. Cao, A. Haelens, F. Claessens, M. P. Revelo, and K. E. Knudsen. 2008. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res. 68: 4551-4558.
5. Hernández, J., A. Ko, and L. A. Sherman. 2001. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166: 3908-3914. (Pubitemid 32224917)
6. Fassò, M., R. Waitz, Y. Hou, T. Rim, N. M. Greenberg, N. Shastri, L. Fong, and J. P. Allison. 2008. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc. Natl. Acad. Sci. USA 105: 3509-3514. (Pubitemid 351723583)
7. Yuan, J., S. Gnjatic, H. Li, S. Powel, H. F. Gallardo, E. Ritter, G. Y. Ku, A. A. Jungbluth, N. H. Segal, T. S. Rasalan, et al. 2008. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105: 20410-20415.
8. Fong, L., S. S. Kwek, S. O'Brien, B. Kavanagh, D. G. McNeel, V. Weinberg, A. M. Lin, J. Rosenberg, C. J. Ryan, B. I. Rini, and E. J. Small. 2009. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69: 609-615.
9. Jinushi, M., F. S. Hodi, and G. Dranoff. 2006. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 103: 9190-9195. (Pubitemid 43902554)
10. Armitage, J. O. 1998. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92: 4491-4508. (Pubitemid 29005850)
11. Markowicz, S., and E. G. Engleman. 1990. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. 85: 955-961. (Pubitemid 20087502)
12. Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95: 10067-10071. (Pubitemid 28415295)
13. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95: 14863-14868. (Pubitemid 29003722)
14. Team, R. D. C. 2005. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
15. Gentleman, R. C., V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, et al. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5: R80.
16. Biragyn, A., P. A. Ruffini, C. A. Leifer, E. Klyushnenkova, A. Shakhov, O. Chertov, A. K. Shirakawa, J. M. Farber, D. M. Segal, J. J. Oppenheim, and L. W. Kwak. 2002. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298: 1025-1029. (Pubitemid 35247310)
17. Hudson, M. E., I. Pozdnyakova, K. Haines, G. Mor, and M. Snyder. 2007. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl. Acad. Sci. USA 104: 17494-17499. (Pubitemid 350219866)
18. Yang, F., X. Li, M. Sharma, M. Zarnegar, B. Lim, and Z. Sun. 2001. Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. J. Biol. Chem. 276: 15345-15353.
19. Webber, M. M., D. Bello, H. K. Kleinman, D. D. Wartinger, D. E. Williams, and J. S. Rhim. 1996. Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis 17: 1641-1646. (Pubitemid 26280386)
20. Webber, M. M., D. Bello, H. K. Kleinman, and M. P. Hoffman. 1997. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18: 1225-1231. (Pubitemid 28132514)
21. Fong, L., C. L. Ruegg, D. Brockstedt, E. G. Engleman, and R. Laus. 1997. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159: 3113-3117. (Pubitemid 127482067)
22. Foster, B. A., J. R. Gingrich, E. D. Kwon, C. Madias, and N. M. Greenberg. 1997. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57: 3325-3330. (Pubitemid 27355467)
23. Watson, P. A., K. Ellwood-Yen, J. C. King, J. Wongvipat, M. M. Lebeau, and C. L. Sawyers. 2005. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65: 11565-11571. (Pubitemid 41821715)
24. Jones, S., X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
25. Taylor, B. S., N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
26. Tesniere, A., T. Panaretakis, O. Kepp, L. Apetoh, F. Ghiringhelli, L. Zitvogel, and G. Kroemer. 2008. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15: 3-12. (Pubitemid 350286167)
27. McNeel, D. G., L. D. Nguyen, W. J. Ellis, C. S. Higano, P. H. Lange, and M. L. Disis. 2001. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 47: 222-229. (Pubitemid 32378374)
28. Wen, X., X. Li, B. Liao, Y. Liu, J. Wu, X. Yuan, B. Ouyang, Q. Sun, and X. Gao. 2009. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel. Urology 73: 1407-1411.
29. Zhang, M., M. Siedow, G. Saia, and A. Chakravarti. 2010. Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate 70: 807-816.